Image

Melanoma Research

Featured image for “AIM’s Latest Newsletter: The Research Edition, July 2023”
08/01/2023

AIM’s Latest Newsletter: The Research Edition, July 2023

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research. This edition features: Letter from AIM’s…
Blog - Melanoma360
Melanoma Research
Featured image for “Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma”
05/30/2023

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

May 26, 2023 17:30 ET| Source: Iovance Biotherapeutics, Inc. Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Blog - Melanoma360
Melanoma Research
Featured image for “A Letter From Our Vice President | January 2023”
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Blog - Melanoma360
Melanoma Research
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Blog - Melanoma360
Melanoma Research
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Blog - Melanoma360
Melanoma Research
Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center”
05/25/2022

Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center

Dr. Zeynep Eroglu is a medical oncologist at Moffitt Cancer Center in Florida. Dr. Eroglu’s research interests are translational and…
Blog - Melanoma360
Melanoma Research
08/01/2023

AIM’s Latest Newsletter: The Research Edition, July 2023

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research. This edition features: Letter from AIM’s…
Featured image for “AIM’s Latest Newsletter: The Research Edition, July 2023”
Blog - Melanoma360
 | 
Melanoma Research
05/30/2023

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

May 26, 2023 17:30 ET| Source: Iovance Biotherapeutics, Inc. Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date…
Featured image for “Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Featured image for “A Letter From Our Vice President | January 2023”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
Blog - Melanoma360
 | 
Melanoma Research
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
05/25/2022

Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center

Dr. Zeynep Eroglu is a medical oncologist at Moffitt Cancer Center in Florida. Dr. Eroglu’s research interests are translational and…
Featured image for “Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center”
Blog - Melanoma360
 | 
Melanoma Research